Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 5.10%
As of Thursday, September 17, Tango Therapeutics, Inc.’s TNGX share price has surged by 5.10%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Commentary & Analysis
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 8.99%
As of Wednesday, September 09, Tango Therapeutics, Inc.’s TNGX share price has surged by 8.99%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Down 5.42%
As of Friday, August 28, Tango Therapeutics, Inc.’s TNGX share price has dipped by 5.42%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 6.12%
As of Wednesday, August 26, Tango Therapeutics, Inc.’s TNGX share price has surged by 6.12%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Tango Therapeutics, Inc.’s (TNGX) Stock Is Up 7.19%
As of Friday, August 21, Tango Therapeutics, Inc.’s TNGX share price has surged by 7.19%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,960.7 | $272.4 | 64% |
|
| Shares Out (Mil) | 149.9 | 54.6 | 71% |
|
| Institutional Ownership | 98.9% | 92.9% | 83% |
|
| Float (Mil) | 120.3 | 42.3 | 64% |
|
| Beta | 1.15 | 0.94 | 68% |
|
| Avg Daily Volume (000s) | 2,397 | 526 | 85% |
|
| Price Change (52-week) |
219.6% | 54.9% | 98% |
|
| Growth | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 52.0% | 14.1% | 96% |
|
| Net Income (5yr) | (14.3%) | (10.1%) | 26% |
|
| EPS (5yr) | 11.7% | 15.4% | 50 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.8% | (15.6%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | 11 | |
| Current EPS | ($0.351) | ($1.396) | ($1.685) | |
| Month Ago EPS | ($0.348) | ($1.384) | ($1.636) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.335) | ($1.318) | ($1.567) | |
| Year/Year Chg | (4.9%) | 59.5% | 121.8% | |
| Financials | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $54 | $37 | 20% |
|
| Net Income (TTM) (Mil) | ($124) | ($43) | 9% |
|
| EPS (TTM) | ($0.915) | ($1.600) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($144) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $306 | $2 | 87% |
|
| Long-Term Debt (Q1) (Mil) | $29 | $4 | 35% |
|
| Enterprise Value (Q1) (Mil) | $3,459 | $182 | 56% |
|
| Valuation | TNGX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.86 | 2.62 | 73% |
|
| P/E | na | 19.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | TNGX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (148.4%) | 69.0% | 1% |
|
| Net Margin | (229.9%) | (73.0%) | 4% |
|
| ROA | (18.9%) | (47.7%) | 21% |
|
| ROE | (21.3%) | (55.0%) | 23% |
|
| Liabilities to Assets | 4.6% | 29.3% | 2% |
|
| F-Score | 4 | 2 | 33% |
|
Tango Therapeutics, Inc. did not pass any screens on 9/17/2026.
